This new class of medications targets the calcitonin gene-related peptide (CGRP), which is believed to play a critical role in migraine. There are three other drugs in this class that are aimed at FDA approval in the coming months. During clinical trials, all of these meds have done remarkably well: more effective than the meds currently used for migraine prevention, and with fewer side effects. This could be life-changing!"The drug, Aimovig [erenumab-aooe], made by Amgen and Novartis, is a monthly injection with a device similar to an insulin pen. The list price will be $6,900 a year, and Amgen said the drug will be available to patients within a week." (https://www.nytimes.com/2018/05/17/health/migraines-prevention-drug-aimovig.html)
Further reading:
- https://www.amgen.com/media/news-releases/2018/05/fda-approves-aimovig-erenumabaooe-a-novel-treatment-developed-specifically-for-migraine-prevention/
- http://www.businessinsider.com/fda-approves-amgen-novartis-preventive-migraine-medication-aimovig-2018-5
- https://americanmigrainefoundation.org/understanding-migraine/cgrp-drug-migraine-facebook-live-recap/
